New study tests common antidepressant for PTSD in military and civilian groups
NCT ID NCT05422612
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 38 times
Summary
This phase 2 study is testing whether fluoxetine, a widely used antidepressant, can reduce PTSD symptoms in 800 adults including active-duty service members, veterans, and civilians. Participants receive either fluoxetine or a placebo for 12 weeks, and researchers measure changes in PTSD severity using a standard clinical scale. The study also monitors for side effects like suicidal thoughts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-TRAUMATIC STRESS DISORDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Advanced Discovery Research
RECRUITINGAtlanta, Georgia, 30318, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Alexander T. Augusta Military Medical Center (ATAMMC):
RECRUITINGFort Belvoir, Virginia, 22060-5285, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cincinnati Veteran's Affairs Medical Center
RECRUITINGFort Thomas, Kentucky, 41075, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Homestead Associates in Research, Inc.
RECRUITINGMiami, Florida, 33032, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Madigan Army Medical Center
RECRUITINGJoint Base Lewis McChord, Washington, 98433, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tripler Army Medical Center (TAMC)
RECRUITINGTripler AMC, Hawaii, 96859, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Upstate Clinical Research Associates, LLC
RECRUITINGWilliamsville, New York, 14221, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Walter Reed National Military Medical Center (WRNMC)
RECRUITINGBethesda, Maryland, 20889-5632, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Wilford Hall Ambulatory Surgical Center (WHASC)
RECRUITINGSan Antonio, Texas, 78236, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fluoxetine (a common antidepressant)
What this could lead to
If successful, this could provide a reliable treatment option to reduce PTSD symptoms in military and civilian populations.
What could go wrong
This is an early phase 2 trial with 800 participants, so results may not confirm effectiveness. Fluoxetine is already used for depression, but its benefit for PTSD is not proven, and side effects like suicidal thoughts are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.